Tempest Therapeutics announced its Q3 2025 financial results and business update on Wednesday, 2025‑11‑05, reporting its latest financial performance for the quarter ended September 30, 2025.
In the update, the company reiterated its ongoing strategic alternatives process aimed at maximizing shareholder value and highlighted the upcoming start of the TPST‑1495 Phase 2 study in collaboration with the National Cancer Institute and the Cancer Prevention Clinical Trials Network.
The company expressed confidence in the potential of its lead candidate, amezalpat, to transform first‑line hepatocellular carcinoma treatment, underscoring its commitment to advancing the pipeline despite financial constraints.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.